PDRN supplements: can you swallow your way to the “salmon DNA” skin trend?
Share
PDRN has moved from aesthetic clinics into skincare conversations at remarkable speed. It is often introduced as “salmon DNA”, but the more useful question is how it reaches the skin. A substance injected into tissue, placed in a cream and swallowed in a capsule encounters three very different biological environments. The evidence for one route cannot simply be transferred to another.
What actually is PDRN?
Polydeoxyribonucleotide, or PDRN, is a preparation of DNA fragments, traditionally obtained from salmon or trout. It is related to, but should not automatically be treated as identical to, the longer polynucleotides used in some aesthetic procedures. Researchers are interested in its potential effects on tissue repair and inflammatory signalling, including pathways involving the adenosine A2A receptor. Much of that mechanistic work comes from laboratory, animal and wound-healing research [1, 2].
Clinical aesthetic evidence is emerging, but remains relatively small. A systematic review of polynucleotide injections included nine studies and 219 patients. Several reported improvements in wrinkles, texture or elasticity, while the authors rated the underlying evidence low to moderate quality [3]. Those are studies of procedures delivered to skin. They are not trials of an oral supplement.
What changes when PDRN is put in a capsule?
An oral product must pass through digestion before any ingredient or metabolite could have an effect elsewhere in the body. To establish a skin benefit, a manufacturer would need evidence for the actual oral preparation: what survives digestion, what is absorbed, the dose used, and whether people taking it experience better skin outcomes than a placebo group. A plausible tissue-repair mechanism does not answer those questions. The published PDRN reviews we examined focus on injected, locally applied or experimental uses; they do not establish equivalent skin results from swallowing PDRN [1–3].
An oral product must pass through digestion before any ingredient or metabolite could have an effect elsewhere in the body. To establish a skin benefit, a manufacturer would need evidence for the actual oral preparation: what survives digestion, what is absorbed, the dose used, and whether people taking it experience better skin outcomes than a placebo group. A plausible tissue-repair mechanism does not answer those questions. The published PDRN reviews we examined focus on injected, locally applied or experimental uses; they do not establish equivalent skin results from swallowing PDRN [1–3].
Even topical products need their own evidence. An attractive ingredient story, a laboratory result and a finished serum tested on human skin are different levels of proof. Formulation, concentration and delivery matter. It is reasonable to be curious about this area without claiming that every product labelled PDRN performs like a clinic treatment.
The Form Co. view
The useful question is not whether an ingredient is trending. It is whether its form, route and finished-product evidence match the result being promised. PDRN is an interesting area of skin research. Oral PDRN for visible skin outcomes remains an open question. Skin Calm™ does not contain PDRN; this post is an evidence check on a trend, rather than a claim about our formula.
The useful question is not whether an ingredient is trending. It is whether its form, route and finished-product evidence match the result being promised. PDRN is an interesting area of skin research. Oral PDRN for visible skin outcomes remains an open question. Skin Calm™ does not contain PDRN; this post is an evidence check on a trend, rather than a claim about our formula.
SOURCES
1. Park et al. (2025), review of PDRN in skin disorders: www.mdpi.com
2. Lee et al. (2024), polynucleotides in aesthetic medicine: pmc.ncbi.nlm.nih.gov
3. Lampridou et al. (2025), systematic review of polynucleotide injections: pubmed.ncbi.nlm.nih.gov
1. Park et al. (2025), review of PDRN in skin disorders: www.mdpi.com
2. Lee et al. (2024), polynucleotides in aesthetic medicine: pmc.ncbi.nlm.nih.gov
3. Lampridou et al. (2025), systematic review of polynucleotide injections: pubmed.ncbi.nlm.nih.gov